Our work also identifies the adaptive response of low FOXO3 expression to boost drug survival and the overdependence on elevated PERK activity to overcome heightened ER-stress, as an acquired vulnerability of the drug-resistant cancer cells. Here, FOXO3 is linked to cancer.